NCT03741972View on ClinicalTrials.gov

Metabolic and Hemodynamic Effects of the Inhibitors of Type 2 Sodium Glucose Co-transporters (ISGLT2) in Diabetic Patients With Heart Failure

CompletedOBSERVATIONAL
Enrollment

100

Participants

Timeline

Start Date

December 21, 2018

Primary Completion Date

April 4, 2022

Study Completion Date

April 4, 2022

Conditions
Heart Failure
Interventions
DRUG

iSGTL2

Treatment with empaglifozine 10 mg/day (may be also dapaglifozine 10mg/day depending on clinical trial results)

Trial Locations (1)

Unknown

Germans Trias i Pujol University Hospital, Badalona

All Listed Sponsors
lead

Germans Trias i Pujol Hospital

OTHER

NCT03741972 - Metabolic and Hemodynamic Effects of the Inhibitors of Type 2 Sodium Glucose Co-transporters (ISGLT2) in Diabetic Patients With Heart Failure | Biotech Hunter | Biotech Hunter